Letrozole

證據等級: L5

預測適應症: 10 個

Letrozole: From Aromatase Inhibition to Female Breast Carcinoma

One-Sentence Summary

Letrozole is a third-generation non-steroidal aromatase inhibitor that suppresses circulating estrogen by more than 99% in postmenopausal women, globally established as the backbone endocrine therapy for hormone receptor-positive breast cancer — though currently unregistered in the Philippines. The TxGNN model predicts it is highly effective for Female Breast Carcinoma with a confidence score of 99.98%, supported by 50+ registered clinical trials and 20+ publications — including multiple landmark Phase 3 RCTs (BIG 1-98, PALOMA-2, MONALEESA-2) that have cemented it as an international standard of care.

Quick Overview

Item	Content
Original Indication	No Philippines registration on record; globally approved for HR+/HER2-negative breast cancer
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.98%
Evidence Level	L1
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Letrozole competitively and selectively inhibits CYP19A1 (aromatase), the enzyme that converts adrenal androgens (androstenedione, testosterone) to estrogens (estrone, estradiol) in peripheral tissues and the tumor microenvironment. This results in >99% suppression of circulating estrogen in postmenopausal women — effectively cutting off the primary proliferative signal that drives estrogen receptor-positive (ER+) breast cancer cells. Unlike tamoxifen, which blocks ER binding, Letrozole eliminates the ligand itself, making it particularly potent in settings of high local aromatase activity.

The biological rationale is direct and reinforced by decades of clinical data: ER+ breast cancer cells depend on estrogen-driven ERα transcription to activate growth-promoting genes such as cyclin D1, c-Myc, and IGF-1R. Letrozole’s near-complete estrogen depletion arrests this pathway, causing tumour regression in both early and advanced disease. Its established synergy with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) — which block cell-cycle progression downstream of the same ER signalling axis — has made the combination a first-line global standard since 2016.

It is important to note that, while Letrozole is not currently registered in the Philippines, the TxGNN model’s prediction of 99.98% essentially recapitulates the overwhelming global consensus. This report therefore serves as an evidence-based argument for market introduction, highlighting both the strength of the existing data package and the key guardrails required before local deployment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01740427	Phase 3	Completed	666	PALOMA-2: Palbociclib + Letrozole vs. Letrozole alone as first-line therapy for postmenopausal ER+/HER2- ABC; Letrozole arm serves as the benchmark for all subsequent first-line CDK4/6i combinations
NCT02338310	Phase 3	Active, not recruiting	4,486	TOPIC: Perioperative Letrozole followed by standard adjuvant therapy vs. standard therapy alone; evaluates Ki67 suppression after 2-week AI as an individualised predictor of recurrence-free survival
NCT05163106	Phase 2	Completed	85	NEOLETRIB: Ribociclib + Letrozole as neoadjuvant treatment in stage III locally advanced breast cancer; demonstrates feasibility of replacing chemotherapy with CDK4/6i + AI combinations
NCT02600923	Phase 3	Completed	131	Palbociclib + Letrozole expanded access for Latin American HR+/HER2- ABC; confirms tolerability and Letrozole-based regimen effectiveness in diverse populations
NCT00291135	Phase 2	Completed	42	Six months of Letrozole in high-risk postmenopausal women on HRT; direct assessment of Letrozole single-agent effect on breast tissue biomarkers (Ki67, ER) in a chemoprevention context
NCT02692755	Phase 2/3	Completed	35	Palbociclib + Letrozole/Fulvestrant in African American women with HR+/HER2- ABC; prospectively evaluated haematological safety in an under-represented population
NCT00754845	Phase 3	Completed	1,918	Extended adjuvant Letrozole vs. placebo after completing 5 years of prior aromatase inhibitor (MA.17 extension); assessed efficacy of prolonged oestrogen suppression
NCT00171704	Phase 3	Completed	263	Head-to-head Letrozole vs. Tamoxifen effects on bone mineral density and lipid profiles in adjuvant ER+ early breast cancer; key safety dataset for long-term use
NCT03056755	Phase 2	Completed	383	BYLieve: Alpelisib + Letrozole (or Fulvestrant) in PIK3CA-mutated HR+/HER2- ABC after prior CDK4/6i progression; Letrozole as endocrine backbone in PIK3CA-pathway combinations
NCT04553133	Phase 2	Active, not recruiting	154	Phase 1/2 dose escalation of PF-07104091 ± Letrozole in advanced breast and ovarian cancers; Letrozole as combination backbone to evaluate novel CDK2 inhibition

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16382061	2005	RCT Phase 3 (BIG 1-98)	N Engl J Med	Letrozole superior to tamoxifen as adjuvant therapy in postmenopausal ER+ early breast cancer; established Letrozole as the adjuvant aromatase inhibitor reference standard
27959613	2016	RCT Phase 3 (PALOMA-2)	N Engl J Med	Palbociclib + Letrozole significantly prolonged PFS (27.6 vs 14.5 months, HR 0.58) vs. Letrozole alone in first-line HR+/HER2- ABC; confirmed CDK4/6i + Letrozole as global standard
35263519	2022	RCT Phase 3 OS (MONALEESA-2)	N Engl J Med	Ribociclib + Letrozole demonstrated significant overall survival benefit vs. Letrozole alone in HR+/HER2- ABC (median OS 63.9 vs 51.4 months)
29718092	2018	RCT Phase 3 Update (MONALEESA-2)	Ann Oncol	Updated MONALEESA-2: ribociclib + letrozole maintained PFS superiority; exploratory biomarker analyses identified PIK3CA mutation and CCND1/CDK4 pathway features as informative markers
38507751	2024	RCT Phase 3 (NATALEE)	N Engl J Med	Ribociclib + NSAI (letrozole or anastrozole) as adjuvant therapy significantly improved iDFS (HR 0.75) vs. NSAI alone in HR+/HER2- early breast cancer; extends CDK4/6i indication to the curative setting
30475668	2019	RCT Phase 3 Long-term FU (BIG 1-98)	J Clin Oncol	BIG 1-98 12.6-year follow-up: sustained disease-free and overall survival benefit of letrozole vs. tamoxifen in postmenopausal ER+ breast cancer; late recurrence data inform extended therapy strategies
35464999	2022	RCT	Comput Math Methods Med	Sequential tamoxifen → letrozole vs. letrozole monotherapy in breast carcinoma: letrozole arm demonstrated superior efficacy outcomes and comparable safety profile
32683565	2020	RCT Phase 2 OS (PALOMA-1)	Breast Cancer Res Treat	PALOMA-1 OS analysis: palbociclib + letrozole vs. letrozole alone — confirmed PFS benefit (HR 0.488); OS trend favoured combination arm
38729566	2024	RCT Phase 3 OS (MONARCH 3)	Ann Oncol	Abemaciclib + NSAI (including letrozole/anastrozole) as initial therapy for HR+/HER2- ABC: final OS analysis demonstrated significant survival benefit, validating CDK4/6i + aromatase inhibitor as standard first-line
36243120	2022	Review	Life Sci	Comprehensive review of Letrozole pharmacology, toxicology, and therapeutic applications across adjuvant, neoadjuvant, and metastatic breast cancer settings; covers mechanism, PK/PD, and emerging uses

Philippines Market Information

Letrozole currently has no registered products in the Philippines (FDA Philippines). There are zero marketing authorizations, no approved indications, and no licensed dosage forms on record. This is a notable gap given Letrozole’s status as a globally approved essential medicine recommended by the WHO, ESMO, NCCN, and ASCO for HR+/HER2-negative breast cancer treatment.

Cytotoxicity

Letrozole is an antineoplastic agent used in breast cancer treatment. It is classified as endocrine/hormonal therapy and is not conventional cytotoxic chemotherapy.

Item	Content
Cytotoxicity Classification	Hormonal antineoplastic — non-steroidal aromatase inhibitor (triazole class); targeted endocrine mechanism, not DNA-damaging cytotoxic
Myelosuppression Risk	Low — aromatase inhibitors do not suppress bone marrow hematopoiesis; routine CBC monitoring is not required beyond baseline
Emetogenicity Classification	Minimal — oral daily tablet; standard antiemetic prophylaxis not indicated
Monitoring Items	Bone mineral density (DEXA scan at baseline and annually); lipid profile; liver function tests; arthralgia/myalgia assessment; cardiovascular risk factors in postmenopausal patients
Handling Protection	Standard pharmaceutical handling applies; cytotoxic drug handling precautions (closed-system transfer, PPE for hazardous drugs) are not required for Letrozole

Safety Considerations

Detailed Philippines-specific safety labeling is unavailable as Letrozole is not currently registered. Please refer to the international package insert and established clinical safety data for guidance. From the published trial literature, key known adverse effects include musculoskeletal symptoms (arthralgia, myalgia), bone mineral density reduction with long-term use, hot flashes, fatigue, and hypercholesterolaemia.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for Letrozole in female breast carcinoma is among the strongest in oncology — multiple completed Phase 3 RCTs consistently demonstrate superior efficacy over tamoxifen in the adjuvant setting and establish it as the endocrine backbone for CDK4/6 inhibitor combinations. The TxGNN score of 99.98% reflects this global consensus. The critical blocker is the complete absence of Philippines regulatory registration and the identified data gaps in local safety documentation.

To proceed, the following is needed:

Philippines FDA registration dossier: Compile the existing international NDA/MAA data package (BIG 1-98, PALOMA-2, MONALEESA-2 as pivotal studies) for submission to the Food and Drug Administration of the Philippines
Philippines package insert: Develop local prescribing information with Philippines-specific pharmacovigilance requirements and YMYL-compliant patient information materials
Safety gap remediation: Obtain full drug interaction database (DDI data gap DG001 remains unresolved); acquire TFDA/PMDA/EMA label warnings and contraindications (DG001/DG002)
Bone health management protocol: Establish baseline and periodic DEXA monitoring guidelines adapted to the Philippines oncology care infrastructure
Pharmacoeconomic assessment: Evaluate cost-effectiveness and affordability within the Philippine Health Insurance Corporation (PhilHealth) reimbursement framework
Supply and access planning: Identify local distributors, confirm oral tablet cold-chain requirements, and assess availability of 2.5 mg tablet formulation

Disclaimer: This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.